Truth is that valuing our patent at $80M in preclinical stage may be low as in the last 5 months there have been published multiple studies that are supportive of our drug candidate.
Our closest competitor may be Chantix. Since 2006 Chantix has generated every year almost $1B in revenues! That's ~$13B from date.
That's because it's patented and insurances are paying for it. Chantix patent is expiring this year in nov.
We're already pushing it forward in pre-clinical stage, but it may be wise to land a partner. There's zero doubt that we will find a partner, it will come to the matter who's offering us the best deal and the news is imminent.
Drug manufacturers/developers are paying advance even for just manufacturing rights and for the right for first negotiations.
Joke is shorts being in denial about it, their paper profits will soon be worthless.
News 
Market Data 
Discover 
